2257. Cost-Benefit Analysis of Fidaxomicin (FDX) as First Line Treatment for Initial Episode of Clostridioides difficile Infection (CDI) during the COVID-19 Pandemic: A Quality Control/Improvement (QC/QI) Project at a Tertiary Care Veterans Affairs Medical Center (VAMC) over a 4-year period

BACKGROUND: In 2021, Clostridioides difficile infection treatment guidelines were updated to recommend fidaxomicin over oral vancomycin as first-line therapy for initial and recurrent episodes of CDI. The aim of this analysis is to evaluate the cost benefit advantage of using fidaxomicin as first li...

Descripción completa

Detalles Bibliográficos
Autores principales: Khaja, Sumaiya F, Kuhn, Ryan, Ali, Sajjad, Natesan, Suganthini Krishnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676969/
http://dx.doi.org/10.1093/ofid/ofad500.1879

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10676969/
http://dx.doi.org/10.1093/ofid/ofad500.1879

Ejemplares similares